PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
- Registry ID
- B1481022
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- PFIZER CANADA INC
- Start date
- 2014-08-13
- Last update
- 2014-05-16
Conditions
- MAJOR CARDIOVASCULAR EVENTS
Related clinical trials
- A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0616 IN REDUCING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PARTICIPANTS AT HIGH CARDIOVASCULAR RISK
- A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE IMPACT OF EVOLOCUMAB ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS AT HIGH CARDIOVASCULAR RISK WITHOUT PRIOR MYOCARDIAL INFARCTION OR STROKE
- INFLUENZA VACCINE TO EFFECTIVELY STOP CARDIO THORACIC EVENTS AND DECOMPENSATED HEART FAILURE (INVESTED)
- PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
View on source registry